| Name | Title | Contact Details |
|---|---|---|
George Francis |
Chief Information Officer | Profile |
Jonathan Waldern |
Chief Technology Officer | Profile |
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Viacord is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NPS Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Beta Bionics is proud to be a Massachusetts public benefit corporation.
Morphotek is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.